首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1859303

青蒿素联合治疗市场报告：趋势、预测和竞争分析（至2031年）

Artemisinin Combination Therapy Market Report: Trends, Forecast and Competitive Analysis to 2031

出版日期: 2025年11月03日 | 出版商:

Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录图表

由于医院和诊所市场的巨大机会，全球青蒿素联合治疗市场前景广阔。预计2025年至2031年，全球青蒿素联合治疗市场将以8.2%的复合年增长率成长。该市场的主要驱动因素是其已被证实能够快速清除寄生虫血症、缓解症状、提高治疗成功率并预防抗药性疟原虫株的出现。

Lucintel 预测，按类型划分，由于蒿甲醚加苯芴醇在治疗併发症疟疾方面具有卓越的疗效和安全性，预计在预测期内将实现最高增长。
从应用角度来看，诊所预计将呈现高速成长，因为治疗通常在诊所进行，尤其是在疟疾流行地区。
按地区划分，由于输入性疟疾病例数量不断增加以及对有效治疗方案的需求，预计北美在预测期内仍将是最大的地区。

青蒿素联合治疗市场的新趋势

由于技术、监管和研发等方面的许多发展，青蒿素联合治疗市场正在迅速转型。这些趋势反映了疟疾控制领域不断演变的挑战，例如抗药性和定价问题，同时也凸显了治疗领域创新和成长的机会。以下新兴趋势正在重塑青蒿素联合疗法市场，推动其朝向更有效、更容易取得和永续的解决方案：

联合疗法创新：青蒿素与其他抗疟疾药的固定剂量复方製剂（FDC）因其使用方便、患者依从性高而日益普及。 FDC 将多种药物组合成一片药片，降低了抗药性风险，并改善了治疗效果。製药公司正在研发疗程更短、疗效更佳的 FDC，使其在大规模疟疾控制计画中发挥重要作用。预计这一趋势将推动对青蒿素类复方製剂（ACT）的需求，尤其是在疟疾高发国家。
日益重视抗药性管理：青蒿素类药物的抗药性已成为一个日益严重的问题，研究人员正致力于开发新药和新策略来克服这一难题。抗药性管理方法，包括新的青蒿素类复方製剂和替代药物，在市场上的重要性日益凸显。这一趋势正在影响研究方向，并推动创新药物的研发，这些药物能够维持青蒿素类复方製剂的疗效，尤其是在东南亚和撒哈拉以南非洲等受抗药性疟原虫株影响的地区。
官民合作关係：政府、国际组织和私人製药公司之间的合作对于改善疟疾流行地区获得青蒿素联合疗法（ACT）的机会至关重要。官民合作关係（PPP）是确保低收入国家能够负担得起并获得ACT的关键。此类伙伴关係正在扩大生产和分销规模，并开发新型ACT製剂。透过公私合作，相关人员旨在扩大全球供应链，降低成本，并提高疟疾流行最严重地区获得ACT疗法的机会。
给药机制的进步：青蒿素联合疗法（ACT）市场正在经历药物递送系统的进步，旨在提高疗效和患者依从性。诸如控制释放製剂和注射用ACT等创新技术正在研究中，以提供更有效的给药方案。预计这一趋势将提高ACT的疗效，尤其是在医疗资源匮乏或无法进行口服治疗的地区。这些创新有助于克服疟疾治疗在后勤方面面临的挑战。
整合数位健康：数位健康技术正被纳入疟疾控制项目，以改善监测、诊断和治疗依从性。行动健康应用、远端医疗和数据分析正被越来越多地用于即时追踪青蒿素联合疗法（ACT）的疗效。数位平台也为病患教育提供支持，并提高大众对疟疾预防和治疗的认识。这些趋势正在改变ACT的分发和监测格局，并加强全球应对疟疾的行动。

青蒿素联合治疗（ACT）市场正受到一系列新兴趋势的影响，这些趋势反映出疟疾治疗和控制领域对创新解决方案日益增长的需求。联合药物製剂、抗药性管理策略以及数位医疗的整合等创新，都有助于提供更有效、更容易取得且更永续的治疗方案。官民合作关係以及药物传递机制的进步，进一步提升了ACT计画在全球的推广规模。

青蒿素联合治疗市场近期趋势

青蒿素联合治疗（ACT）市场正经历着显着的发展，反映了全球疟疾应对措施的演变。这些趋势受到新治疗方法进展、国际合作以及旨在提高ACT疗效、可负担性和可及性的监管更新的影响。以下关键发展阐述了ACT市场如何变革以应对当前和未来疟疾治疗的挑战。

新型青蒿素联合疗法（ACT）製剂的推出：近年来，ACT市场的发展趋势包括推出新型製剂，这些製剂将青蒿素与吡咯萘啶和他非诺喹等新伙伴药物相结合。这些新组合的研发旨在对抗抗药性并提高治疗效果。例如，吡咯萘啶-蒿甲醚复方製剂的推出，作为传统ACT的替代方案，旨在解决东南亚地区青蒿素抗药性问题。这些新型製剂有望为疟疾治疗提供更永续的解决方案。
扩大非专利ACT生产：在印度、中国和其他一些国家，非专利ACT的生产正在扩大，这有助于降低疟疾流行地区疟疾治疗的费用，并提高其可及性。对于低收入国家而言，获得价格合理的非专利ACT对于疟疾控制计画的成功至关重要。这一趋势正在促进ACT的广泛应用，尤其是在政府卫生计画的推动下，并减轻疟疾治疗的经济负担。
加强全球合作与资金筹措：来自全球抗击爱滋病、结核病和疟疾基金（GFATM）和世界卫生组织（WHO）等组织的全球合作与筹资正在提高流行地区青蒿素类复方药物（ACTs）的可及性。这些合作的重点是扩大ACTs的分发范围、改善医疗卫生基础设施以及投资疟疾研究。加强资金筹措机制和伙伴关係在扩大撒哈拉以南非洲和其他高负担地区ACTs的使用方面发挥关键作用。
聚焦疟疾消除：多个国家已承诺在2030年前消除疟疾，而青蒿素联合疗法（ACT）是这些国家策略的核心。中国和印度等国正透过加强ACT供应链、提高诊断和治疗率以及将ACT的使用纳入更广泛的公共卫生计划，推进其疟疾消除工作。这些努力正在加速低疟疾传播但持续存在的地区对ACT的推广，降低疟疾传播率，并朝着全球消除疟疾的目标迈进。
青蒿素类复方药物（ACT）核准监管进展：美国食品药物管理局（FDA）和欧洲药品管理局（EMA）等监管机构近期核准了新的ACT组合和製剂。这些监管进展简化了ACT的核准流程，使患者能够更快地获得创新治疗方法。随着新的组合和替代疗法的核准，全球ACT市场正在走向多元化，为疟疾治疗提供了更多选择，尤其是在面临青蒿素抗药性的地区。

近年来，青蒿素联合治疗（ACT）市场的发展趋势主要集中在提高药物疗效、扩大药物可及性以及应对抗药性等挑战。新型製剂的推出、学名药的增加以及全球合作正在扩大疟疾流行地区ACT的覆盖范围。疟疾消除工作的进展和监管核准的不断改进正在重塑市场格局，而ACT製剂的技术创新也不断改善治疗效果。

概述
吸引力分析：按类型
青蒿醚+苯芴醇：趋势与预测（2019-2031）
青蒿琥酯+阿莫地喹：趋势与预测（2019-2031）
青蒿素+哌喹：趋势与预测（2019-2031）
青蒿琥酯+甲氟喹：趋势与预测（2019-2031）
青蒿琥酯+磺胺多辛-乙胺嘧啶：趋势与预测（2019-2031）
吡咯萘啶-青蒿琥酯：趋势与预测（2019-2031）
其他：趋势与预测（2019-2031 年）

5. 全球青蒿素联合治疗市场（依应用划分）

概述
吸引力分析：依目的
医院：趋势与预测（2019-2031）
医疗诊所：趋势与预测（2019-2031）
其他：趋势与预测（2019-2031 年）

第六章区域分析

概述
全球青蒿素联合治疗市场（按地区划分）

7. 北美青蒿素联合治疗市场

概述
北美青蒿素联合治疗市场（按青蒿素划分）
北美青蒿素联合治疗市场（按青蒿素划分）
美国青蒿素联合治疗市场
墨西哥青蒿素联合治疗市场
加拿大青蒿素联合治疗市场

8. 欧洲青蒿素联合治疗市场

概述
欧洲青蒿素联合治疗市场（按类型划分）
欧洲青蒿素联合治疗市场（按应用划分）
德国青蒿素联合治疗市场
法国青蒿素联合治疗市场
西班牙青蒿素联合治疗市场
义大利青蒿素联合治疗市场
英国青蒿素联合治疗市场

9. 亚太地区青蒿素联合治疗市场

概述
亚太地区青蒿素联合治疗市场（按类型划分）
亚太地区青蒿素联合治疗市场（按应用划分）
日本青蒿素联合治疗市场
印度青蒿素联合治疗市场
中国青蒿素联合治疗市场
韩国青蒿素联合治疗市场
印尼青蒿素联合治疗市场

10. 世界其他地区（ROW）青蒿素联合治疗市场

概述
ROW青蒿素联合治疗市场（按类型划分）
ROW青蒿素联合治疗市场按应用领域划分
中东青蒿素联合治疗市场
南美洲青蒿素联合治疗市场
非洲青蒿素联合治疗市场

第十一章竞争分析

产品系列分析
营运整合
波特五力分析
- 竞争对手之间的竞争
- 买方议价能力
- 供应商的议价能力
- 替代品的威胁
- 新进入者的威胁
市占率分析

第十二章：机会与策略分析

价值链分析
成长机会分析
- 按类型分類的成长机会
- 透过申请获得发展机会
全球青蒿素联合治疗市场新兴趋势
战略分析
- 新产品开发
- 认证和许可
- 企业合併、协议、合作关係和合资企业

第十三章：价值链中主要企业的概况

竞争分析
KPC Pharmaceuticals
Sanofi
Desano Holdings
Mylan
Novartis

第十四章附录

图表清单
表格列表
分析方法
免责声明
版权
简称和技术单位
关于 Lucintel
询问

简介目录图表

The future of the global artemisinin combination therapy market looks promising with opportunities in the hospital, clinic markets. The global artemisinin combination therapy market is expected to grow with a CAGR of 8.2% from 2025 to 2031. The major drivers for this market are its demonstrated effectiveness in quickly eliminating parasitemia, alleviating symptoms enhances treatment success rates, and prevent the emergence of drug-resistant malaria strains.

Lucintel forecasts that, within the type category, artemether+lumefantrine is expected to witness the highest growth over the forecast period due to its superior effectiveness and safety in treating uncomplicated malaria.
Within the application category, clinic is expected to witness the higher growth due to treatments are commonly administered in clinics, especially in malaria-endemic regions.
In terms of region, North America will remain the largest region over the forecast period due to the rising number of imported malaria cases and the need for effective treatment options.

Emerging Trends in the Artemisinin Combination Therapy Market

The Artemisinin Combination Therapy market is undergoing rapid transformation, driven by various technological, regulatory, and research developments. These trends reflect the evolving challenges in malaria control, such as drug resistance and affordability, while also highlighting opportunities for innovation and growth in the treatment landscape. The following emerging trends are reshaping the ACT market and pushing it toward more effective, accessible, and sustainable solutions.

Innovation in Fixed-Dose Combinations: Fixed-dose combinations (FDCs) of artemisinin and other antimalarial drugs are gaining momentum due to their ease of use and improved patient adherence. By combining multiple drugs into a single tablet, FDCs reduce the risk of resistance and improve treatment outcomes. Pharmaceutical companies are developing more efficient FDCs with shorter treatment durations, making them highly effective for large-scale malaria control programs. This trend is expected to drive the demand for ACTs, especially in countries with high malaria transmission.
Growing Focus on Resistance Management: As resistance to artemisinin-based therapies becomes a growing concern, researchers are focused on developing new drugs and strategies to overcome this issue. Resistance management initiatives, including new ACT combinations and alternative drugs, are becoming a significant part of the market landscape. This trend is shaping research directions, leading to innovative drug development that can preserve the efficacy of ACT therapies in regions affected by drug-resistant malaria strains, particularly in Southeast Asia and sub-Saharan Africa.
Public-Private Partnerships: The collaboration between governments, international organizations, and private pharmaceutical companies is essential to improving ACT access in malaria-endemic regions. Public-private partnerships (PPPs) are key to ensuring the affordability and availability of ACTs in low-income countries. These partnerships have led to increased production and distribution, as well as the development of novel ACT formulations. Through PPPs, stakeholders aim to increase global supply chains, reduce costs, and expand access to ACT therapies in regions most affected by malaria.
Advances in Delivery Mechanisms: The ACT market is witnessing advancements in drug delivery systems aimed at improving treatment efficacy and patient compliance. Innovations such as controlled-release formulations and injectable ACTs are being explored to provide more efficient dosing regimens. This trend is expected to enhance the effectiveness of ACTs, especially in areas with limited access to healthcare or where oral treatments may not be feasible. These innovations are helping to address the logistical challenges of malaria treatment delivery.
Digital Health Integration: Digital health technologies are being integrated into malaria control programs to improve monitoring, diagnosis, and treatment adherence. Mobile health applications, telemedicine, and data analytics are increasingly used to track the effectiveness of ACT therapies in real time. Digital platforms also support patient education, increasing awareness of malaria prevention and treatment. This trend is reshaping the landscape of ACT distribution and monitoring, enhancing the global response to malaria.

The Artemisinin Combination Therapy (ACT) market is being shaped by a series of emerging trends that reflect the increasing need for innovative solutions in malaria treatment and control. Innovations like fixed-dose combinations, resistance management strategies, and digital health integration are all contributing to more effective, accessible, and sustainable treatment options. Public-private partnerships and advances in drug delivery mechanisms further enhance the scalability of ACT programs globally.

Recent Developments in the Artemisinin Combination Therapy Market

The Artemisinin Combination Therapy (ACT) market is witnessing significant developments that reflect the evolving global response to malaria. These developments are influenced by new therapeutic advancements, international collaborations, and regulatory updates aimed at enhancing the efficacy, affordability, and accessibility of ACTs. The following key developments highlight how the ACT market is transforming to address current and future challenges in malaria treatment.

Introduction of Novel ACT Formulations: Recent developments in the ACT market include the introduction of novel drug formulations that combine artemisinin with new partners, such as pyronaridine and tafenoquine. These new combinations are being developed to combat drug resistance and improve treatment efficacy. For example, the introduction of pyronaridine-artesunate as an alternative to traditional ACTs addresses concerns related to artemisinin resistance in Southeast Asia. These new formulations are expected to provide more durable solutions to malaria treatment.
Expansion of Generic ACT Production: India, China, and several other countries have ramped up the production of generic ACTs, which are helping to make malaria treatment more affordable and accessible in endemic regions. The availability of affordable generic ACTs is critical to the success of malaria control programs in low-income countries. This trend is contributing to the wider distribution of ACTs, especially through government health programs, reducing the economic burden of malaria treatment.
Enhanced Global Collaboration and Funding: Global collaborations and funding from organizations such as the Global Fund to Fight AIDS, Tuberculosis, and Malaria (GFATM) and the World Health Organization (WHO) have increased the availability of ACTs in endemic regions. These collaborations focus on scaling up the distribution of ACTs, improving healthcare infrastructure, and investing in malaria research. Enhanced funding mechanisms and partnerships have played a crucial role in increasing access to ACTs in sub-Saharan Africa and other high-burden regions.
Increased Focus on Malaria Elimination: Several countries have committed to malaria elimination by 2030, and ACT is central to these national strategies. Countries such as China and India are advancing malaria elimination efforts by strengthening ACT supply chains, improving diagnosis and treatment coverage, and integrating ACT use into broader public health programs. These efforts are accelerating the deployment of ACTs in areas with low but persistent malaria transmission, helping to reduce malaria transmission rates and move closer to the goal of global eradication.
Regulatory Advancements in ACT Approvals: Regulatory bodies such as the U.S. FDA and the European Medicines Agency (EMA) have recently approved new ACT combinations and formulations. These regulatory advancements streamline the approval process for ACTs, ensuring quicker access to innovative therapies. With increasing approval of new combinations and alternative drugs, the global market for ACTs is diversifying, offering more options for malaria treatment, especially in areas facing artemisinin resistance.

Recent developments in the Artemisinin Combination Therapy (ACT) market are focused on enhancing drug efficacy, accessibility, and addressing challenges like drug resistance. The introduction of novel formulations, increased generic production, and global collaborations has expanded the availability of ACTs in malaria-endemic regions. Efforts toward malaria eradication and advancements in regulatory approvals are reshaping the market, while innovations in ACT formulations are improving treatment outcomes.

Strategic Growth Opportunities in the Artemisinin Combination Therapy Market

The Artemisinin Combination Therapy (ACT) market is poised for growth, driven by strategic opportunities across various applications. These growth opportunities are linked to innovations in drug formulations, global health initiatives, and the expanding focus on malaria eradication. The following are key growth opportunities by application in the ACT market, each playing a critical role in shaping the future of malaria control and treatment.

Strengthening Malaria Control Programs: A significant growth opportunity lies in strengthening national malaria control programs (NMCPs) in malaria-endemic countries. ACTs play a central role in these programs, where governments are investing in mass drug administration campaigns, integrated vector management, and surveillance systems. Expanding access to ACTs through government-run distribution programs is critical to achieving the World Health Organization's global malaria targets, particularly in regions such as sub-Saharan Africa.
Pediatric Malaria Treatment: Pediatric malaria treatment represents a key growth opportunity, with increasing focus on formulating ACTs that are more suitable for children. Efforts are being made to improve the palatability, dosage, and safety of ACTs for pediatric patients, as this group faces higher mortality rates from malaria. The development of pediatric-friendly ACT formulations and combination therapies is expected to drive market growth in countries with high childhood malaria burden.
Scaling Up Preventative Malaria Treatment: Preventative malaria treatment strategies, such as seasonal malaria chemoprevention (SMC), are gaining momentum. ACTs are integral to these efforts, which involve administering ACTs to individuals in malaria-endemic regions during peak transmission seasons. The scalability of these preventive programs offers significant growth potential for the ACT market, especially in areas where seasonal malaria transmission is a major concern.
Investment in Malaria Vaccine Programs: While vaccines are not yet a complete solution, their integration with ACT treatments presents a unique growth opportunity. Malaria vaccine initiatives, such as the RTS,S/AS01 vaccine, are complementing ACTs in regions with high malaria transmission. The convergence of vaccines and ACTs creates synergies that could improve malaria control, expanding the market for ACTs and providing new channels for distribution and application.
Expansion of Malaria Research and Development: The ongoing research into drug-resistant malaria and new therapies presents an opportunity for growth. Investment in R&D for novel ACTs, combination therapies, and alternative treatment regimens is expected to open new market avenues. As new formulations and treatments are developed, these will complement the current ACT landscape and further drive demand.

These applications collectively contribute to a comprehensive approach to malaria control, opening up avenues for growth and reinforcing global efforts to combat malaria. As these opportunities are harnessed, the ACT market is set to become a central pillar of malaria eradication initiatives.

Artemisinin Combination Therapy Market Driver and Challenges

The Artemisinin Combination Therapy (ACT) market is influenced by various drivers and challenges. These include technological advancements in drug development, economic considerations, and regulatory frameworks. On the one hand, advancements in ACT formulations and collaborations in global health have led to increased market demand. On the other hand, challenges like drug resistance and affordability constraints affect its growth potential. Understanding these dynamics is essential to navigating the market's evolution.

The factors responsible for driving the Artemisinin Combination Therapy market include:

1. Increase in Malaria Cases: The rising incidence of malaria, particularly in sub-Saharan Africa and Southeast Asia, drives the demand for ACTs. With approximately 200 million cases globally, ACTs are critical for controlling outbreaks and improving public health outcomes. The growth in malaria cases in certain regions underscores the need for effective treatment options, supporting the market for ACTs.

2. Government and NGO Support: Governments and international organizations play a pivotal role in funding ACT distribution programs. Agencies like the Global Fund, WHO, and various national health ministries are investing heavily in malaria eradication, increasing the accessibility and availability of ACTs worldwide. This financial and institutional support fosters market expansion, especially in high-burden regions.

3. Advancements in ACT Formulations: Research and development into novel ACT formulations, such as fixed-dose combinations and improved drug delivery mechanisms, are significant drivers. These innovations improve treatment outcomes, reduce side effects, and enhance patient compliance, which makes ACTs more attractive for malaria-endemic countries, boosting market demand.

4. Cost Reduction and Generic Production: The growing production of generic ACTs, particularly by Indian and Chinese pharmaceutical companies, has lowered the cost of malaria treatment. These affordable options are critical for low-income countries, increasing the penetration of ACTs in endemic regions and driving overall market growth.

5. Focus on Malaria Eradication: The global push towards malaria elimination by 2030 provides a strong growth driver for the ACT market. National strategies focused on malaria eradication rely heavily on effective treatment options, with ACTs playing a central role. This focus on eradication ensures sustained demand and strategic investments in the ACT market.

Challenges in the Artemisinin Combination Therapy market are:

1. Drug Resistance: Artemisinin resistance, particularly in Southeast Asia, poses a significant threat to the efficacy of ACTs. The emergence of resistant strains necessitates the development of new ACT combinations and alternatives to maintain effectiveness. Resistance challenges may hinder the widespread use of current ACTs if not addressed.

2. Affordability and Access: While generics have lowered prices, the affordability of ACTs remains a challenge in low-income regions. Issues related to distribution, healthcare infrastructure, and financial barriers affect access to ACTs in the most vulnerable populations, limiting their impact on malaria control.

3. Supply Chain and Distribution Constraints: The global supply chain for ACTs faces logistical challenges, including the timely delivery of drugs to remote and hard-to-reach areas. Inefficient distribution systems and stock outs continue to be barriers, hindering the consistent availability of ACTs when and where they are most needed.

The drivers and challenges in the ACT market are interrelated. While increasing malaria cases and advancements in drug formulations fuel growth, challenges such as resistance and access barriers require attention. Strategic investments and collaborations will be crucial to overcoming these hurdles and ensuring the continued success of ACTs in global malaria control efforts.

List of Artemisinin Combination Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies artemisinin combination therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the artemisinin combination therapy companies profiled in this report include-

KPC Pharmaceuticals
Sanofi
Desano Holdings
Mylan
Novartis

Artemisinin Combination Therapy Market by Segment

The study includes a forecast for the global artemisinin combination therapy market by type, application, and region.

Artemisinin Combination Therapy Market by Type [Value from 2019 to 2031]:

Artemether+Lumefantrine
Artesunate+Amodiaquine
Dihydroartemisinin+Piperaquine
Artesunate+Mefloquine
Artesunate+Sulfadoxine-Pyrimethamine
Pyronaridine-Artesunate
Others

Artemisinin Combination Therapy Market by Application [Value from 2019 to 2031]:

Hospital
Clinic
Other

Artemisinin Combination Therapy Market by Region [Value from 2019 to 2031]:

North America
Europe
Asia Pacific
The Rest of the World

Country Wise Outlook for the Artemisinin Combination Therapy Market

Artemisinin Combination Therapy (ACT) is the gold-standard treatment for malaria, especially in areas with widespread drug-resistant malaria strains. The market for ACT is growing due to rising malaria incidences, particularly in developing countries, but also due to advancements in drug formulations and production methods. Emerging markets, such as China and India, play a critical role in shaping this growth. Meanwhile, developed countries like the United States, Germany, and Japan are focused on supporting global health initiatives and investing in innovative ACT research. Here we explore the key developments, trends, growth opportunities, and challenges in the ACT market in the United States, China, Germany, India, and Japan.

United States: The United States has seen a continued focus on supporting global malaria eradication efforts. A key development in the ACT market is the government's investment in research and development of new drug formulations. The U.S. is also a major supplier of ACT medicines through organizations like the U.S. Agency for International Development (USAID). However, domestically, malaria cases are relatively low, so ACT demand is mainly driven by U.S.-funded international programs. The U.S. is increasingly involved in the deployment of newer ACT formulations in sub-Saharan Africa and Southeast Asia, with an emphasis on cost-effective and efficient therapies.
China: China remains a critical player in the global ACT market. The country has significantly reduced its malaria burden, but it continues to invest heavily in malaria research. China's advancements in manufacturing and producing artemisinin-based therapies have led to cost reductions, making ACT more accessible across Southeast Asia and sub-Saharan Africa. In addition, Chinese companies are increasingly involved in clinical trials to develop next-generation ACT treatments. The government is also focusing on integrating ACT with other public health programs to eradicate malaria by 2030, positioning China as a key hub for innovation and supply in the ACT market.
Germany: Germany's role in the ACT market is largely driven by its commitment to international development and malaria eradication. The country supports the global roll-out of ACT through collaborations with international organizations, including the World Health Organization (WHO). German pharmaceutical companies are also active in improving the efficacy and affordability of ACT, with investments in the development of fixed-dose combination therapies (FDCs). Furthermore, Germany is a key player in malaria research, with its scientific community focusing on the development of new ACT formulations to combat emerging resistance.
India: India, with its large population and high malaria burden, is both a producer and a consumer of ACT. The country has focused on increasing access to ACT for its domestic population, which is critical for controlling malaria transmission. Indian pharmaceutical companies, including Cipla and Dr. Reddy's Laboratories, play a key role in producing affordable generic ACTs, which are distributed through government programs. India is also engaged in developing more efficient and robust ACT formulations to combat drug resistance, with ongoing efforts to improve drug delivery and minimize side effects in the population.
Japan: Japan's involvement in the ACT market is primarily through international development and research. While domestic malaria cases are extremely low, Japan is heavily invested in global malaria eradication efforts. Japan's pharmaceutical industry has made significant contributions to the ACT market through collaborations and research on more effective therapies. Moreover, Japan supports malaria control through organizations like the Japan International Cooperation Agency (JICA), which is focused on funding ACT distribution in malaria-endemic regions, particularly in Southeast Asia and Africa. Japan also plays a crucial role in improving malaria diagnostics and treatment protocols.

Features of the Global Artemisinin Combination Therapy Market

Market Size Estimates: Artemisinin combination therapy market size estimation in terms of value ($M).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Artemisinin combination therapy market size by type, application, and region in terms of value ($M).
Regional Analysis: Artemisinin combination therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the artemisinin combination therapy market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the artemisinin combination therapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the artemisinin combination therapy market by type (artemether+lumefantrine, artesunate+amodiaquine, dihydroartemisinin+piperaquine, artesunate+mefloquine, artesunate+sulfadoxine-pyrimethamine, pyronaridine-artesunate, and others), application (hospital, clinic, and other), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

1. Executive Summary

2. Market Overview

2.1 Background and Classifications
2.2 Supply Chain

3. Market Trends & Forecast Analysis

3.2 Industry Drivers and Challenges
3.3 PESTLE Analysis
3.4 Patent Analysis
3.5 Regulatory Environment

4. Global Artemisinin Combination Therapy Market by Type

4.1 Overview
4.2 Attractiveness Analysis by Type
4.3 Artemether+Lumefantrine: Trends and Forecast (2019-2031)
4.4 Artesunate+Amodiaquine: Trends and Forecast (2019-2031)
4.5 Dihydroartemisinin+Piperaquine: Trends and Forecast (2019-2031)
4.6 Artesunate+Mefloquine: Trends and Forecast (2019-2031)
4.7 Artesunate+Sulfadoxine-Pyrimethamine: Trends and Forecast (2019-2031)
4.8 Pyronaridine-Artesunate: Trends and Forecast (2019-2031)
4.9 Others: Trends and Forecast (2019-2031)

5. Global Artemisinin Combination Therapy Market by Application

5.1 Overview
5.2 Attractiveness Analysis by Application
5.3 Hospital: Trends and Forecast (2019-2031)
5.4 Clinic: Trends and Forecast (2019-2031)
5.5 Other: Trends and Forecast (2019-2031)

6. Regional Analysis

6.1 Overview
6.2 Global Artemisinin Combination Therapy Market by Region

7. North American Artemisinin Combination Therapy Market

7.1 Overview
7.2 North American Artemisinin Combination Therapy Market by Type
7.3 North American Artemisinin Combination Therapy Market by Application
7.4 United States Artemisinin Combination Therapy Market
7.5 Mexican Artemisinin Combination Therapy Market
7.6 Canadian Artemisinin Combination Therapy Market

8. European Artemisinin Combination Therapy Market

8.1 Overview
8.2 European Artemisinin Combination Therapy Market by Type
8.3 European Artemisinin Combination Therapy Market by Application
8.4 German Artemisinin Combination Therapy Market
8.5 French Artemisinin Combination Therapy Market
8.6 Spanish Artemisinin Combination Therapy Market
8.7 Italian Artemisinin Combination Therapy Market
8.8 United Kingdom Artemisinin Combination Therapy Market

9. APAC Artemisinin Combination Therapy Market

9.1 Overview
9.2 APAC Artemisinin Combination Therapy Market by Type
9.3 APAC Artemisinin Combination Therapy Market by Application
9.4 Japanese Artemisinin Combination Therapy Market
9.5 Indian Artemisinin Combination Therapy Market
9.6 Chinese Artemisinin Combination Therapy Market
9.7 South Korean Artemisinin Combination Therapy Market
9.8 Indonesian Artemisinin Combination Therapy Market

10. ROW Artemisinin Combination Therapy Market

10.1 Overview
10.2 ROW Artemisinin Combination Therapy Market by Type
10.3 ROW Artemisinin Combination Therapy Market by Application
10.4 Middle Eastern Artemisinin Combination Therapy Market
10.5 South American Artemisinin Combination Therapy Market
10.6 African Artemisinin Combination Therapy Market

11. Competitor Analysis

11.1 Product Portfolio Analysis
11.2 Operational Integration
11.3 Porter's Five Forces Analysis
- Competitive Rivalry
- Bargaining Power of Buyers
- Bargaining Power of Suppliers
- Threat of Substitutes
- Threat of New Entrants
11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

12.1 Value Chain Analysis
12.2 Growth Opportunity Analysis
- 12.2.1 Growth Opportunities by Type
- 12.2.2 Growth Opportunities by Application
12.3 Emerging Trends in the Global Artemisinin Combination Therapy Market
12.4 Strategic Analysis
- 12.4.1 New Product Development
- 12.4.2 Certification and Licensing
- 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

13.1 Competitive Analysis
13.2 KPC Pharmaceuticals
- Company Overview
- Artemisinin Combination Therapy Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.3 Sanofi
- Company Overview
- Artemisinin Combination Therapy Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.4 Desano Holdings
- Company Overview
- Artemisinin Combination Therapy Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.5 Mylan
- Company Overview
- Artemisinin Combination Therapy Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.6 Novartis
- Company Overview
- Artemisinin Combination Therapy Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing

14. Appendix

14.1 List of Figures
14.2 List of Tables
14.3 Research Methodology
14.4 Disclaimer
14.5 Copyright
14.6 Abbreviations and Technical Units
14.7 About Us
14.8 Contact Us

简介目录图表

List of Figures

Figure 1.1: Trends and Forecast for the Global Artemisinin Combination Therapy Market
Figure 2.1: Usage of Artemisinin Combination Therapy Market
Figure 2.2: Classification of the Global Artemisinin Combination Therapy Market
Figure 2.3: Supply Chain of the Global Artemisinin Combination Therapy Market
Figure 3.1: Driver and Challenges of the Artemisinin Combination Therapy Market
Figure 3.2: PESTLE Analysis
Figure 3.3: Patent Analysis
Figure 3.4: Regulatory Environment
Figure 4.1: Global Artemisinin Combination Therapy Market by Type in 2019, 2024, and 2031
Figure 4.2: Trends of the Global Artemisinin Combination Therapy Market ($B) by Type
Figure 4.3: Forecast for the Global Artemisinin Combination Therapy Market ($B) by Type
Figure 4.4: Trends and Forecast for Artemether+Lumefantrine in the Global Artemisinin Combination Therapy Market (2019-2031)
Figure 4.5: Trends and Forecast for Artesunate+Amodiaquine in the Global Artemisinin Combination Therapy Market (2019-2031)
Figure 4.6: Trends and Forecast for Dihydroartemisinin+Piperaquine in the Global Artemisinin Combination Therapy Market (2019-2031)
Figure 4.7: Trends and Forecast for Artesunate+Mefloquine in the Global Artemisinin Combination Therapy Market (2019-2031)
Figure 4.8: Trends and Forecast for Artesunate+Sulfadoxine-Pyrimethamine in the Global Artemisinin Combination Therapy Market (2019-2031)
Figure 4.9: Trends and Forecast for Pyronaridine-Artesunate in the Global Artemisinin Combination Therapy Market (2019-2031)
Figure 4.10: Trends and Forecast for Others in the Global Artemisinin Combination Therapy Market (2019-2031)
Figure 5.1: Global Artemisinin Combination Therapy Market by Application in 2019, 2024, and 2031
Figure 5.2: Trends of the Global Artemisinin Combination Therapy Market ($B) by Application
Figure 5.3: Forecast for the Global Artemisinin Combination Therapy Market ($B) by Application
Figure 5.4: Trends and Forecast for Hospital in the Global Artemisinin Combination Therapy Market (2019-2031)
Figure 5.5: Trends and Forecast for Clinic in the Global Artemisinin Combination Therapy Market (2019-2031)
Figure 5.6: Trends and Forecast for Other in the Global Artemisinin Combination Therapy Market (2019-2031)
Figure 6.1: Trends of the Global Artemisinin Combination Therapy Market ($B) by Region (2019-2024)
Figure 6.2: Forecast for the Global Artemisinin Combination Therapy Market ($B) by Region (2025-2031)
Figure 7.1: North American Artemisinin Combination Therapy Market by Type in 2019, 2024, and 2031
Figure 7.2: Trends of the North American Artemisinin Combination Therapy Market ($B) by Type (2019-2024)
Figure 7.3: Forecast for the North American Artemisinin Combination Therapy Market ($B) by Type (2025-2031)
Figure 7.4: North American Artemisinin Combination Therapy Market by Application in 2019, 2024, and 2031
Figure 7.5: Trends of the North American Artemisinin Combination Therapy Market ($B) by Application (2019-2024)
Figure 7.6: Forecast for the North American Artemisinin Combination Therapy Market ($B) by Application (2025-2031)
Figure 7.7: Trends and Forecast for the United States Artemisinin Combination Therapy Market ($B) (2019-2031)
Figure 7.8: Trends and Forecast for the Mexican Artemisinin Combination Therapy Market ($B) (2019-2031)
Figure 7.9: Trends and Forecast for the Canadian Artemisinin Combination Therapy Market ($B) (2019-2031)
Figure 8.1: European Artemisinin Combination Therapy Market by Type in 2019, 2024, and 2031
Figure 8.2: Trends of the European Artemisinin Combination Therapy Market ($B) by Type (2019-2024)
Figure 8.3: Forecast for the European Artemisinin Combination Therapy Market ($B) by Type (2025-2031)
Figure 8.4: European Artemisinin Combination Therapy Market by Application in 2019, 2024, and 2031
Figure 8.5: Trends of the European Artemisinin Combination Therapy Market ($B) by Application (2019-2024)
Figure 8.6: Forecast for the European Artemisinin Combination Therapy Market ($B) by Application (2025-2031)
Figure 8.7: Trends and Forecast for the German Artemisinin Combination Therapy Market ($B) (2019-2031)
Figure 8.8: Trends and Forecast for the French Artemisinin Combination Therapy Market ($B) (2019-2031)
Figure 8.9: Trends and Forecast for the Spanish Artemisinin Combination Therapy Market ($B) (2019-2031)
Figure 8.10: Trends and Forecast for the Italian Artemisinin Combination Therapy Market ($B) (2019-2031)
Figure 8.11: Trends and Forecast for the United Kingdom Artemisinin Combination Therapy Market ($B) (2019-2031)
Figure 9.1: APAC Artemisinin Combination Therapy Market by Type in 2019, 2024, and 2031
Figure 9.2: Trends of the APAC Artemisinin Combination Therapy Market ($B) by Type (2019-2024)
Figure 9.3: Forecast for the APAC Artemisinin Combination Therapy Market ($B) by Type (2025-2031)
Figure 9.4: APAC Artemisinin Combination Therapy Market by Application in 2019, 2024, and 2031
Figure 9.5: Trends of the APAC Artemisinin Combination Therapy Market ($B) by Application (2019-2024)
Figure 9.6: Forecast for the APAC Artemisinin Combination Therapy Market ($B) by Application (2025-2031)
Figure 9.7: Trends and Forecast for the Japanese Artemisinin Combination Therapy Market ($B) (2019-2031)
Figure 9.8: Trends and Forecast for the Indian Artemisinin Combination Therapy Market ($B) (2019-2031)
Figure 9.9: Trends and Forecast for the Chinese Artemisinin Combination Therapy Market ($B) (2019-2031)
Figure 9.10: Trends and Forecast for the South Korean Artemisinin Combination Therapy Market ($B) (2019-2031)
Figure 9.11: Trends and Forecast for the Indonesian Artemisinin Combination Therapy Market ($B) (2019-2031)
Figure 10.1: ROW Artemisinin Combination Therapy Market by Type in 2019, 2024, and 2031
Figure 10.2: Trends of the ROW Artemisinin Combination Therapy Market ($B) by Type (2019-2024)
Figure 10.3: Forecast for the ROW Artemisinin Combination Therapy Market ($B) by Type (2025-2031)
Figure 10.4: ROW Artemisinin Combination Therapy Market by Application in 2019, 2024, and 2031
Figure 10.5: Trends of the ROW Artemisinin Combination Therapy Market ($B) by Application (2019-2024)
Figure 10.6: Forecast for the ROW Artemisinin Combination Therapy Market ($B) by Application (2025-2031)
Figure 10.7: Trends and Forecast for the Middle Eastern Artemisinin Combination Therapy Market ($B) (2019-2031)
Figure 10.8: Trends and Forecast for the South American Artemisinin Combination Therapy Market ($B) (2019-2031)
Figure 10.9: Trends and Forecast for the African Artemisinin Combination Therapy Market ($B) (2019-2031)
Figure 11.1: Porter's Five Forces Analysis of the Global Artemisinin Combination Therapy Market
Figure 11.2: Market Share (%) of Top Players in the Global Artemisinin Combination Therapy Market (2024)
Figure 12.1: Growth Opportunities for the Global Artemisinin Combination Therapy Market by Type
Figure 12.2: Growth Opportunities for the Global Artemisinin Combination Therapy Market by Application
Figure 12.3: Growth Opportunities for the Global Artemisinin Combination Therapy Market by Region
Figure 12.4: Emerging Trends in the Global Artemisinin Combination Therapy Market

List of Tables

Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Artemisinin Combination Therapy Market by Type and Application
Table 1.2: Attractiveness Analysis for the Artemisinin Combination Therapy Market by Region
Table 1.3: Global Artemisinin Combination Therapy Market Parameters and Attributes
Table 3.1: Trends of the Global Artemisinin Combination Therapy Market (2019-2024)
Table 3.2: Forecast for the Global Artemisinin Combination Therapy Market (2025-2031)
Table 4.1: Attractiveness Analysis for the Global Artemisinin Combination Therapy Market by Type
Table 4.2: Market Size and CAGR of Various Type in the Global Artemisinin Combination Therapy Market (2019-2024)
Table 4.3: Market Size and CAGR of Various Type in the Global Artemisinin Combination Therapy Market (2025-2031)
Table 4.4: Trends of Artemether+Lumefantrine in the Global Artemisinin Combination Therapy Market (2019-2024)
Table 4.5: Forecast for Artemether+Lumefantrine in the Global Artemisinin Combination Therapy Market (2025-2031)
Table 4.6: Trends of Artesunate+Amodiaquine in the Global Artemisinin Combination Therapy Market (2019-2024)
Table 4.7: Forecast for Artesunate+Amodiaquine in the Global Artemisinin Combination Therapy Market (2025-2031)
Table 4.8: Trends of Dihydroartemisinin+Piperaquine in the Global Artemisinin Combination Therapy Market (2019-2024)
Table 4.9: Forecast for Dihydroartemisinin+Piperaquine in the Global Artemisinin Combination Therapy Market (2025-2031)
Table 4.10: Trends of Artesunate+Mefloquine in the Global Artemisinin Combination Therapy Market (2019-2024)
Table 4.11: Forecast for Artesunate+Mefloquine in the Global Artemisinin Combination Therapy Market (2025-2031)
Table 4.12: Trends of Artesunate+Sulfadoxine-Pyrimethamine in the Global Artemisinin Combination Therapy Market (2019-2024)
Table 4.13: Forecast for Artesunate+Sulfadoxine-Pyrimethamine in the Global Artemisinin Combination Therapy Market (2025-2031)
Table 4.14: Trends of Pyronaridine-Artesunate in the Global Artemisinin Combination Therapy Market (2019-2024)
Table 4.15: Forecast for Pyronaridine-Artesunate in the Global Artemisinin Combination Therapy Market (2025-2031)
Table 4.16: Trends of Others in the Global Artemisinin Combination Therapy Market (2019-2024)
Table 4.17: Forecast for Others in the Global Artemisinin Combination Therapy Market (2025-2031)
Table 5.1: Attractiveness Analysis for the Global Artemisinin Combination Therapy Market by Application
Table 5.2: Market Size and CAGR of Various Application in the Global Artemisinin Combination Therapy Market (2019-2024)
Table 5.3: Market Size and CAGR of Various Application in the Global Artemisinin Combination Therapy Market (2025-2031)
Table 5.4: Trends of Hospital in the Global Artemisinin Combination Therapy Market (2019-2024)
Table 5.5: Forecast for Hospital in the Global Artemisinin Combination Therapy Market (2025-2031)
Table 5.6: Trends of Clinic in the Global Artemisinin Combination Therapy Market (2019-2024)
Table 5.7: Forecast for Clinic in the Global Artemisinin Combination Therapy Market (2025-2031)
Table 5.8: Trends of Other in the Global Artemisinin Combination Therapy Market (2019-2024)
Table 5.9: Forecast for Other in the Global Artemisinin Combination Therapy Market (2025-2031)
Table 6.1: Market Size and CAGR of Various Regions in the Global Artemisinin Combination Therapy Market (2019-2024)
Table 6.2: Market Size and CAGR of Various Regions in the Global Artemisinin Combination Therapy Market (2025-2031)
Table 7.1: Trends of the North American Artemisinin Combination Therapy Market (2019-2024)
Table 7.2: Forecast for the North American Artemisinin Combination Therapy Market (2025-2031)
Table 7.3: Market Size and CAGR of Various type in the North American Artemisinin Combination Therapy Market (2019-2024)
Table 7.4: Market Size and CAGR of Various type in the North American Artemisinin Combination Therapy Market (2025-2031)
Table 7.5: Market Size and CAGR of Various application in the North American Artemisinin Combination Therapy Market (2019-2024)
Table 7.6: Market Size and CAGR of Various application in the North American Artemisinin Combination Therapy Market (2025-2031)
Table 7.7: Trends and Forecast for the United States Artemisinin Combination Therapy Market (2019-2031)
Table 7.8: Trends and Forecast for the Mexican Artemisinin Combination Therapy Market (2019-2031)
Table 7.9: Trends and Forecast for the Canadian Artemisinin Combination Therapy Market (2019-2031)
Table 8.1: Trends of the European Artemisinin Combination Therapy Market (2019-2024)
Table 8.2: Forecast for the European Artemisinin Combination Therapy Market (2025-2031)
Table 8.3: Market Size and CAGR of Various type in the European Artemisinin Combination Therapy Market (2019-2024)
Table 8.4: Market Size and CAGR of Various type in the European Artemisinin Combination Therapy Market (2025-2031)
Table 8.5: Market Size and CAGR of Various application in the European Artemisinin Combination Therapy Market (2019-2024)
Table 8.6: Market Size and CAGR of Various application in the European Artemisinin Combination Therapy Market (2025-2031)
Table 8.7: Trends and Forecast for the German Artemisinin Combination Therapy Market (2019-2031)
Table 8.8: Trends and Forecast for the French Artemisinin Combination Therapy Market (2019-2031)
Table 8.9: Trends and Forecast for the Spanish Artemisinin Combination Therapy Market (2019-2031)
Table 8.10: Trends and Forecast for the Italian Artemisinin Combination Therapy Market (2019-2031)
Table 8.11: Trends and Forecast for the United Kingdom Artemisinin Combination Therapy Market (2019-2031)
Table 9.1: Trends of the APAC Artemisinin Combination Therapy Market (2019-2024)
Table 9.2: Forecast for the APAC Artemisinin Combination Therapy Market (2025-2031)
Table 9.3: Market Size and CAGR of Various type in the APAC Artemisinin Combination Therapy Market (2019-2024)
Table 9.4: Market Size and CAGR of Various type in the APAC Artemisinin Combination Therapy Market (2025-2031)
Table 9.5: Market Size and CAGR of Various application in the APAC Artemisinin Combination Therapy Market (2019-2024)
Table 9.6: Market Size and CAGR of Various application in the APAC Artemisinin Combination Therapy Market (2025-2031)
Table 9.7: Trends and Forecast for the Japanese Artemisinin Combination Therapy Market (2019-2031)
Table 9.8: Trends and Forecast for the Indian Artemisinin Combination Therapy Market (2019-2031)
Table 9.9: Trends and Forecast for the Chinese Artemisinin Combination Therapy Market (2019-2031)
Table 9.10: Trends and Forecast for the South Korean Artemisinin Combination Therapy Market (2019-2031)
Table 9.11: Trends and Forecast for the Indonesian Artemisinin Combination Therapy Market (2019-2031)
Table 10.1: Trends of the ROW Artemisinin Combination Therapy Market (2019-2024)
Table 10.2: Forecast for the ROW Artemisinin Combination Therapy Market (2025-2031)
Table 10.3: Market Size and CAGR of Various type in the ROW Artemisinin Combination Therapy Market (2019-2024)
Table 10.4: Market Size and CAGR of Various type in the ROW Artemisinin Combination Therapy Market (2025-2031)
Table 10.5: Market Size and CAGR of Various application in the ROW Artemisinin Combination Therapy Market (2019-2024)
Table 10.6: Market Size and CAGR of Various application in the ROW Artemisinin Combination Therapy Market (2025-2031)
Table 10.7: Trends and Forecast for the Middle Eastern Artemisinin Combination Therapy Market (2019-2031)
Table 10.8: Trends and Forecast for the South American Artemisinin Combination Therapy Market (2019-2031)
Table 10.9: Trends and Forecast for the African Artemisinin Combination Therapy Market (2019-2031)
Table 11.1: Product Mapping of Artemisinin Combination Therapy Suppliers Based on Segments
Table 11.2: Operational Integration of Artemisinin Combination Therapy Manufacturers
Table 11.3: Rankings of Suppliers Based on Artemisinin Combination Therapy Revenue
Table 12.1: New Product Launches by Major Artemisinin Combination Therapy Producers (2019-2024)
Table 12.2: Certification Acquired by Major Competitor in the Global Artemisinin Combination Therapy Market

02-2729-4219

+886-2-2729-4219

License/价格

青蒿素联合治疗市场报告：趋势、预测和竞争分析（至2031年）

Artemisinin Combination Therapy Market Report: Trends, Forecast and Competitive Analysis to 2031